Gene V. Wallenstein
Genentech · 131 works · 9,918 citations · h-index 36
Top works
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
- Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
- The hippocampus as an associator of discontiguous events
- A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- GABAergic Modulation of Hippocampal Population Activity: Sequence Learning, Place Field Development, and the Phase Precession Effect
- Gamma Frequency–Range Abnormalities to Auditory Stimulation in Schizophrenia
- Encoding and retrieval of episodic memories: Role of cholinergic and GABAergic modulation in the hippocampus
- Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference
- Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations
- Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference
- SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial
- Burden of Premenstrual Dysphoric Disorder on Health-Related Quality of Life
- Burden of restless legs syndrome on health-related quality of life
- Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial
- Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors